<DOC>
	<DOCNO>NCT01448928</DOCNO>
	<brief_summary>This study regulatory post marketing surveillance Japan , local prospective observational study patient receive Zevalin relapse refractory , CD20+ , low grade B-cell non-Hodgkin 's lymphoma Mantle cell lymphoma . The objective study ass safety efficacy use Zevalin clinical practice . This study also case investigation enrollment period five year , patient receive Zevalin recruit follow 13 week administration .</brief_summary>
	<brief_title>Zevalin Post-marketing Surveillance Japan</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients receive Zevalin relapse refractory : CD20+ low grade Bcell nonHodgkin 's lymphoma Mantle cell lymphoma Patients contraindicate base product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Zevalin</keyword>
	<keyword>CD20+</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Mantle Cell Lymphoma</keyword>
</DOC>